Ascension-St John Hospital, Grosse Pointe Woods, and Wayne State University School of Medicine, East Lansing.
Central Michigan University College of Medicine, Grosse Pointe Woods, East Lansing.
Clin Infect Dis. 2020 Feb 3;70(4):704-709. doi: 10.1093/cid/ciz640.
Plazomicin (ACHN-490) is a novel parenteral aminoglycoside developed to target multidrug-resistant Enterobacteriaceae. It has recently been approved by the Food and Drug Administration for the management of complicated urinary tract infections and pyelonephritis caused by susceptible organisms. When compared with meropenem, plazomicin was not inferior. The adverse-event profile for plazomicin was comparable to meropenem except for an increased additional rise in serum creatinine in the plazomicin arm compared with the meropenem arm. This review focuses on the mode of action, antimicrobial activity, pharmacokinetics, clinical indications, and safety profile of this drug. Considerations for formulary addition and its place in therapy are also discussed.
泊沙康唑（ACHN-490）是一种新型的注射用氨基糖苷类药物，旨在针对多重耐药的肠杆菌科细菌。该药最近已获美国食品药品监督管理局批准，用于治疗敏感病原体引起的复杂性尿路感染和肾盂肾炎。与美罗培南相比，泊沙康唑疗效不劣。除了与美罗培南组相比，泊沙康唑组血清肌酐升高的附加发生率增加外，泊沙康唑的不良事件谱与美罗培南相当。本综述重点介绍了该药的作用模式、抗菌活性、药代动力学、临床适应证和安全性特征。还讨论了纳入处方的考虑因素及其在治疗中的地位。
